Internal Server Error

Avenue Therapeutics - About the company

Avenue Therapeutics is an acquired company based in New York City (United States), founded in 2015. It operates as a Neurologic disease specialty pharmaceutical company developing impactful therapies for unmet needs. Avenue Therapeutics has raised an undisclosed amount in funding, with last known valuation of $*****. The company has 2784 active competitors, including 915 funded and 697 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, argenx and Sana Biotechnology.

Company Details

Neurologic disease specialty pharmaceutical company developing impactful therapies for unmet needs. The company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is advancing a diverse portfolio that includes first-in-class and best-in-class programs in a high-value neurologic landscape with significant unmet patient need. The company aims to deliver impactful therapies to patients suffering from neurologic diseases. They believe their unique pipeline of innovative treatments has the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. The company is involved in pharmaceutical development, commercialization, and therapeutic innovation within the healthcare and life sciences industries.
Social
X
Email ID
*****@avenuetx.com
Key Metrics
Founded Year
2015
Location
New York City, United States
Stage
Acquired
Latest Funding Round
Last Known Valuation
$***** as on Jun 30, 2017
Ranked
Annual Revenue
$1M - $10M as on Dec 31, 2025
Employee Count
10 as on Sep 30, 2026
Similar Companies
Exit Details
Acquired by Cipla (Nov 13, 2018)

Avenue Therapeutics's acquisition details

Avenue Therapeutics got acquired by Cipla on Nov 13, 2018.
Click here to take a look at Avenue Therapeutics's acquisition in detail
Sign up to download Avenue Therapeutics' company profile

Avenue Therapeutics's funding and investors

Avenue Therapeutics has raised funding over 2 rounds. Its first funding round was on Jan 06, 2017.

Here is the list of recent funding rounds of Avenue Therapeutics:
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Jan 31, 2023
6882589
Post IPO
8891981
9677880
3960053
9379172
Jan 06, 2017
3646086
Conventional Debt
3824208
3170836
4036007
8230026
lockAccess funding benchmarks and valuations. Sign up today!

Avenue Therapeutics' founders and board of directors

Founder? Claim Profile

Avenue Therapeutics' employee count trend

Avenue Therapeutics has 10 employees as of Sep 26. Here is Avenue Therapeutics's employee count trend over the years:
Employee count trend for Avenue Therapeutics
lockUncover Avenue Therapeutics' growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Avenue Therapeutics's Competitors and alternates

Top competitors of Avenue Therapeutics include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Here is the list of Top 10 competitors of Avenue Therapeutics, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Jazz Pharmaceuticals
Jazz Pharmaceuticals
2003, Dublin (Ireland), Public
Developer of novel biopharmaceutical medicines for unmet medical needs
$265M
81/100
2nd
Logo for argenx
argenx
2008, Ghent (Belgium), Public
Developer of antibody-based drugs to treat autoimmune diseases and cancer
$61.9M
75/100
3rd
Logo for Sana Biotechnology
Sana Biotechnology
2018, Seattle (United States), Public
Developer of engineered cell therapies for treating various human diseases
$821M
74/100
4th
Logo for Ideaya Biosciences
Ideaya Biosciences
2015, San Francisco (United States), Public
Developer of oncology-focused precision medicine using molecular diagnostics
$157M
73/100
5th
Developer of antibody-based therapeutics for cancer therapy
$175M
72/100
6th
Logo for Syndax
Syndax
2005, Waltham (United States), Public
Developer of targeted therapies for the treatment of cancer
$198M
72/100
7th
Logo for Immuneel
Immuneel
2018, Bengaluru (India), Series B
Developer of T-cell therapies for the treatment of cancer
$49.8M
72/100
8th
Logo for C4 Therapeutics
C4 Therapeutics
2016, Cambridge (United States), Public
Developer of small molecule drugs for treating cancer
$223M
71/100
9th
Logo for Erasca
Erasca
2018, San Diego (United States), Public
Developer of small molecule based therapeutics for cancer
$300M
71/100
10th
Logo for Elicio
Elicio
2012, Cambridge (United States), Public
Developer of vaccines for treating cancer
$47.4M
71/100
781st
Logo for Avenue Therapeutics
Avenue Therapeutics
2015, New York City (United States), Acquired
Neurologic disease specialty pharmaceutical company developing impactful therapies for unmet needs
-
-
42/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Avenue Therapeutics's competitors? Click here to see the top ones

Avenue Therapeutics's Investments and acquisitions

Avenue Therapeutics has made no investments or acquisitions yet.

Reports related to Avenue Therapeutics

Here is the latest report on Avenue Therapeutics's sector:

News related to Avenue Therapeutics

lockFilter this list
Media has covered Avenue Therapeutics for a total of 2 events in the last 1 year.
•
Allarity Therapeutics announces new CFOSeeking Alpha•Sep 13, 2024•Allarity Therapeutics, Avenue Therapeutics
•
Avenue Therapeutics files to sell 1.42M sharesSeeking Alpha•May 06, 2024•Avenue Therapeutics
•
Avenue Therapeutics drops 9% on 1-for-75 reverse splitSeeking Alpha•Apr 24, 2024•Avenue Therapeutics
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Avenue Therapeutics

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford